Open AccessAcute Onset Pancreatitis in the Third Trimester of Pregnancy in HBV Carrier Women Taking Telbivudine for Blocking Mother-to-Infant Transmission
Author(s) -
Haofeng Xiong,
Jingyuan Liu,
Haodong Cai,
Jun Cheng
Publication year - 2014
Publication title -
infection international/infection international (electronic edition)
Language(s) - English
Resource type - Journals
eISSN - 2544-0349
pISSN - 2095-2244
DOI - 10.1515/ii-2017-0072
Subject(s) - medicine , acute pancreatitis , pregnancy , abdominal pain , hypertriglyceridemia , pancreatitis , vomiting , pediatrics , obstetrics , telbivudine , surgery , hepatitis b virus , immunology , triglyceride , genetics , cholesterol , biology , virus , lamivudine
Acute pancreatitis in pregnancy (APIP) is rare and the reasons for APIP are biliary disease and congenital or acquired hypertriglyceridemia, which could occur during any trimester but more than 50% cases happened during the third trimester. In this report, one case of a young pregnant woman, a HBV carrier in her 37th week + 5 d of gestation, was admitted to Emergency Department due to acute abdominal pain, vomiting and diarrhea. The patient was in antiretroviral treatment with telbivudine from 28 weeks of gestation to prevent motherto- child transmission of HBV. Laboratory tests demonstrated hypertriglyceridemia, abdominal computed tomography scan revealed peripancreatic edema. Hyperlipidemic pancreatitits was primary diagnosed and the patient was admitted to the intensive care unit. Considering the possible role in the pathogenesis of pancreatitis, telbivudine was interrupted after birth giving. After supportive treatment, her condition gradually improved. Since it is the first description of APIP during treatment with telbivudine, the association between pregnancy, hyperlipidemia, telbivudine and acute pancreatitis has been well investigated.